Canada markets closed

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.0300-0.1000 (-2.42%)
At close: 04:00PM EDT
5.1500 +1.12 (+27.79%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close4.1300
Open4.1300
Bid4.1500 x 1200
Ask5.1500 x 2900
Day's Range3.9500 - 4.2000
52 Week Range2.8400 - 45.0000
Volume112,827
Avg. Volume238,171
Market Cap84.578M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.8820
Earnings DateMay 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.02
  • GlobeNewswire

    Longeveron Names Jerome Bailey Vice President of Business Operations

    Executive brings more than 30 years of global biopharmaceutical operations and program management experienceMIAMI, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it has named Jerome Bailey as the company’s new vice president of business operations. He joins the company from Checkmate Pharmaceuticals (acquired by Regeneron), where he served as senior director of pr

  • GlobeNewswire

    Longeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference

    MIAMI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and Chief Medical Officer at Longeveron, will present at the upcoming H.C. Wainwright 24th Annual Global Investment Conference taking place in New York City from September 12-14, 2022. Longeve

  • GlobeNewswire

    U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron’s Lomecel-B™ Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants

    New designation may expedite FDA review and potential approval to address this life-threatening heart condition affecting approximately 1,000 babies per yearMIAMI, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Lomecel-B™ for t